163 related articles for article (PubMed ID: 11367260)
1. New anti-HIV drug interactions, toxicities, and dosing options.
Bartnof HS
BETA; 1999; 12(4):60-3, 66. PubMed ID: 11367260
[TBL] [Abstract][Full Text] [Related]
2. Lipodystrophy--nukes vs. protease inhibitors.
TreatmentUpdate; 2001 Jul; 13(3):5-6. PubMed ID: 11569989
[No Abstract] [Full Text] [Related]
3. Fat, sugar and drugs on the French Riviera.
Lands L
GMHC Treat Issues; 1999 Mar; 13(3):9-11. PubMed ID: 11366205
[TBL] [Abstract][Full Text] [Related]
4. On the trail of fugitive fat: the chase turns to NRTIs.
Mascolini M
J Int Assoc Physicians AIDS Care; 1999 Oct; 5(10):24-43. PubMed ID: 11366871
[TBL] [Abstract][Full Text] [Related]
5. Anti-HIV therapies early in the pipeline.
Bartnof HS
BETA; 1999; 12(4):57. PubMed ID: 11367256
[TBL] [Abstract][Full Text] [Related]
6. Mitochondrial toxicity induced by nucleoside-analogue reverse-transcriptase inhibitors is a key factor in the pathogenesis of antiretroviral-therapy-related lipodystrophy.
Brinkman K; Smeitink JA; Romijn JA; Reiss P
Lancet; 1999 Sep; 354(9184):1112-5. PubMed ID: 10509516
[TBL] [Abstract][Full Text] [Related]
7. Anti-HIV therapy trials: new studies and follow-up of existing trials.
Bartnof HS
BETA; 1999; 12(4):58-60. PubMed ID: 11367257
[TBL] [Abstract][Full Text] [Related]
8. ICAAC update.
Coppedge B
STEP Perspect; 1996; 8(3):15-6. PubMed ID: 11364265
[TBL] [Abstract][Full Text] [Related]
9. Focus on fat.
TreatmentUpdate; 2002 Nov; 14(8):4. PubMed ID: 12501822
[No Abstract] [Full Text] [Related]
10. Standard dosing schedule for anti-HIV drugs.
Proj Inf Perspect; 1998 Dec; (26):12-3. PubMed ID: 11366489
[TBL] [Abstract][Full Text] [Related]
11. Drug interactions, toxicities, dosages: trials and tribulations and cocktails.
Crit Path AIDS Proj; 1998; (No 33):9-17. PubMed ID: 11366377
[TBL] [Abstract][Full Text] [Related]
12. The development of lipodystrophy on a protease inhibitor-sparing highly active antiretroviral therapy regimen.
Leitz G; Robinson P
AIDS; 2000 Mar; 14(4):468-9. PubMed ID: 10770555
[No Abstract] [Full Text] [Related]
13. Selected highlights from ICAAC (Interscience Conference on Antimicrobial Agents and Chemotherapy).
TreatmentUpdate; 2002 Jan; 14(1):5-10. PubMed ID: 12141238
[No Abstract] [Full Text] [Related]
14. Clinical significance of treatment-induced lipid abnormalities and lipodystrophy.
Smith D
J HIV Ther; 2001 May; 6(2):25-7. PubMed ID: 11501199
[No Abstract] [Full Text] [Related]
15. Choosing the right initial antiretroviral regimens.
Norton M
GMHC Treat Issues; 1999 Feb; 13(2):7-10. PubMed ID: 11366117
[TBL] [Abstract][Full Text] [Related]
16. Standard treatments for HIV, Spring 1997.
Smith D
AIDS Treat News; 1997 Apr; (No 269):4-5. PubMed ID: 11364255
[TBL] [Abstract][Full Text] [Related]
17. Double jeopardy: the hazards of drug-drug interactions.
Flexner C
Res Initiat Treat Action; 1998 Dec; 4(7):3-8. PubMed ID: 11366084
[TBL] [Abstract][Full Text] [Related]
18. Drug interactions studied at ICAAC.
Gaylord G
Posit Living; 1999 Nov; 8(10):47. PubMed ID: 11367333
[TBL] [Abstract][Full Text] [Related]
19. First once-daily drug simplifies dosing, offers new options in HIV-1 treatment.
AIDS Alert; 1998 Nov; 13(11):121-4. PubMed ID: 11365967
[TBL] [Abstract][Full Text] [Related]
20. Mitigation of hepato-cellular injury caused by HAART with glycyrrhizin compound in patients co-infected with HIV and HCV.
Yamamoto Y; Yasuoka A; Tachikawa N; Teruya K; Genka I; Yamaguchi M; Yasuoka C; Kikuchi Y; Aoki M; Oka S
Jpn J Infect Dis; 1999 Dec; 52(6):248-9. PubMed ID: 10738365
[No Abstract] [Full Text] [Related]
[Next] [New Search]
